Literature DB >> 29721584

[Therapy-resistant and therapy-refractory arterial hypertension].

M Wallbach1, M J Koziolek2.   

Abstract

Therapy-resistant and therapy-refractory arterial hypertension differ in prevalence, pathogenesis, prognosis and therapy. In both cases, a structured approach is required, with the exclusion of pseudoresistance and, subsequently, secondary hypertension. Resistant hypertension has been reported to be more responsive to intensified diuretic therapy, whereas refractory hypertension is presumed to require sympathoinhibitory therapy. Once the general measures and the drug-based step-up therapy have been exhausted, interventional procedures are available.

Entities:  

Keywords:  Baroreflex; Hypertension, secondary; Patient adherence; Pseudoresistance; Renal denervation

Mesh:

Substances:

Year:  2018        PMID: 29721584     DOI: 10.1007/s00108-018-0430-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  28 in total

1.  Low-dose spironolactone in the management of resistant hypertension: a surveillance study.

Authors:  Deirdre A Lane; Sarah Shah; D Gareth Beevers
Journal:  J Hypertens       Date:  2007-04       Impact factor: 4.844

Review 2.  Resistant Hypertension: Insights on Evaluation and Management in the Post-SPRINT (Systolic Blood Pressure Intervention Trial) Era.

Authors:  Raymond R Townsend; Murray Epstein
Journal:  Hypertension       Date:  2016-09-06       Impact factor: 10.190

3.  Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial.

Authors:  Melvin D Lobo; Paul A Sobotka; Alice Stanton; John R Cockcroft; Neil Sulke; Eamon Dolan; Markus van der Giet; Joachim Hoyer; Stephen S Furniss; John P Foran; Adam Witkowski; Andrzej Januszewicz; Danny Schoors; Konstantinos Tsioufis; Benno J Rensing; Benjamin Scott; G André Ng; Christian Ott; Roland E Schmieder
Journal:  Lancet       Date:  2015-01-23       Impact factor: 79.321

Review 4.  Refractory versus resistant hypertension.

Authors:  Mohammed Siddiqui; David A Calhoun
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-01       Impact factor: 2.894

5.  Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.

Authors:  Jan Václavík; Richard Sedlák; Martin Plachy; Karel Navrátil; Jirí Plásek; Jirí Jarkovsky; Tomás Václavík; Roman Husár; Eva Kociánová; Milos Táborsky
Journal:  Hypertension       Date:  2011-05-02       Impact factor: 10.190

6.  Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence.

Authors:  Larissa Grigoryan; Valory N Pavlik; David J Hyman
Journal:  J Am Soc Hypertens       Date:  2013-07-23

7.  Refractory versus resistant hypertension: Novel distinctive phenotypes.

Authors:  Tanja Dudenbostel; Mohammed Siddiqui; Nitin Gharpure; David A Calhoun
Journal:  J Nat Sci       Date:  2017-09

Review 8.  How to Screen for Non-Adherence to Antihypertensive Therapy.

Authors:  Pankaj Gupta; Prashanth Patel; Robert Horne; Heather Buchanan; Bryan Williams; Maciej Tomaszewski
Journal:  Curr Hypertens Rep       Date:  2016-12       Impact factor: 5.369

Review 9.  Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future.

Authors:  Felix Mahfoud; Roland E Schmieder; Michel Azizi; Atul Pathak; Horst Sievert; Costas Tsioufis; Thomas Zeller; Stefan Bertog; Peter J Blankestijn; Michael Böhm; Michel Burnier; Gilles Chatellier; Isabelle Durand Zaleski; Sebastian Ewen; Guido Grassi; Michael Joner; Sverre E Kjeldsen; Melvin D Lobo; Chaim Lotan; Thomas Felix Lüscher; Gianfranco Parati; Patrick Rossignol; Luis Ruilope; Faisal Sharif; Evert van Leeuwen; Massimo Volpe; Stephan Windecker; Adam Witkowski; William Wijns
Journal:  Eur Heart J       Date:  2017-11-21       Impact factor: 29.983

10.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.